Belrestotug

• Pharmacodynamic Assessment of a-TIGIT mAb EOS-448/GSK4428859A Highlights Multiple FcγR-mediated Mode-of-actions in Blood and Tumor of Patients with Advanced Solid Tumors.
  Cuende J, et al. Poster presented at: AACR Annual Meeting 2022
• Preliminary data from Phase 1 first-in-human study of EOS884448, a novel potent anti-TIGIT antibody, monotherapy shows favorable tolerability profile and early signs of clinical activity in immune-resistant advanced cancers.
  Van den Mooter TFA, et al. Poster Presented at: AACR Annual Meeting 2021
• Restoration of T-cell Effector Function, Depletion of Tregs, and Direct Killing of Tumor Cells: The Multiple Mechanisms of Action of a-TIGIT Antagonist Antibodies​​.
  Preillon J, et al. Mol Cancer Ther. 2021;20(1):121-131

Back

EOS-984

• Inhibition of ENT1 relieves intracellular adenosine-mediated T cell suppression in cancer.
  Sanders TJ, et al. Nat Immunol. 2025; Published online: 12 May 2025
• Intracellular adenosine drives profound lymphocyte suppression and can be reversed with EOS-984, a potent ENT1 antagonist.
  Houthuys E, et al. Poster presented at: ESMO Immuno-Oncology Congress 2024
• A Novel Tumor Adenosine Signature to Guide Indication Selection for Adenosine Pathway Inhibitors.
  Dekoninck S, et al. Poster Presented at: ESMO Immuno-Oncology Congress 2024
• Inhibition of equilibrative nucleoside transporter 1 relieves intracellular adenosine-mediated immune suppression.
  Sanders TJ, et al. Poster Presented at: AACR Annual Meeting 2024

Back

EOS-215

• EOS-215, a first-in-class TREM2 antagonist, designed to reprogram the tumor microenvironment and overcome resistance.
  Pirson R, et al. Poster presented at: AACR Annual Meeting 2025

Back